endocrine and metabolic disorders
Amyloidosis
Prognosis for Amyloidosis
Prognosis depends on the type of amyloidosis and the organ system involved, but with appropriate disease-specific and supportive care, many patients have an excellent life expectancy. AL complicated by severe cardiomyopathy has the poorest prognosis, with median survival of < 1 year. Untreated ATTR amyloidosis usually progresses to end-stage cardiac or neurologic disease within 5 to 15 years. ATTRwt was once thought to have the slowest progression of any systemic amyloidosis involving the heart; however, patients with ATTRwt do progress to symptomatic heart failure and death within a median of 4 years from biopsy diagnosis. Prognosis in AA amyloidosis depends largely upon the effectiveness of treatment of the underlying infectious, inflammatory, or malignant disorder. 